FR2852957B1 - Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament - Google Patents

Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament

Info

Publication number
FR2852957B1
FR2852957B1 FR0303924A FR0303924A FR2852957B1 FR 2852957 B1 FR2852957 B1 FR 2852957B1 FR 0303924 A FR0303924 A FR 0303924A FR 0303924 A FR0303924 A FR 0303924A FR 2852957 B1 FR2852957 B1 FR 2852957B1
Authority
FR
France
Prior art keywords
medicinal product
pyridine derivatives
novel imidazo
receptors
imidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0303924A
Other languages
English (en)
French (fr)
Other versions
FR2852957A1 (fr
Inventor
Lydie Poitout
Valerie Brault
Carole Sackur
Pierre Roubert
Pascale Plas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Original Assignee
Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0303924A priority Critical patent/FR2852957B1/fr
Application filed by Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS filed Critical Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Priority to MXPA05010278A priority patent/MXPA05010278A/es
Priority to AU2004228416A priority patent/AU2004228416B9/en
Priority to JP2006505764A priority patent/JP4711948B2/ja
Priority to BRPI0408817-4A priority patent/BRPI0408817A/pt
Priority to EP04742386A priority patent/EP1615925B1/fr
Priority to CNB2004800084919A priority patent/CN100455581C/zh
Priority to ES04742386T priority patent/ES2327929T3/es
Priority to KR1020057018420A priority patent/KR101102742B1/ko
Priority to PCT/FR2004/000785 priority patent/WO2004089951A1/fr
Priority to NZ542763A priority patent/NZ542763A/en
Priority to US10/550,122 priority patent/US7495009B2/en
Priority to DE602004021247T priority patent/DE602004021247D1/de
Priority to RU2005133441/04A priority patent/RU2358974C2/ru
Priority to HK06111349.9A priority patent/HK1090640B/xx
Priority to CA2520855A priority patent/CA2520855C/fr
Priority to AT04742386T priority patent/ATE432280T1/de
Publication of FR2852957A1 publication Critical patent/FR2852957A1/fr
Application granted granted Critical
Publication of FR2852957B1 publication Critical patent/FR2852957B1/fr
Priority to IL170834A priority patent/IL170834A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
FR0303924A 2003-03-31 2003-03-31 Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament Expired - Fee Related FR2852957B1 (fr)

Priority Applications (18)

Application Number Priority Date Filing Date Title
FR0303924A FR2852957B1 (fr) 2003-03-31 2003-03-31 Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament
US10/550,122 US7495009B2 (en) 2003-03-31 2004-03-29 Imidazopyridine derivatives as melancortin receptor agonists
JP2006505764A JP4711948B2 (ja) 2003-03-31 2004-03-29 新規イミダゾピリジン誘導体及びその医薬としての使用
BRPI0408817-4A BRPI0408817A (pt) 2003-03-31 2004-03-29 composto, processo de preparação do mesmo, composição farmacêutico, e, utilização de um composto
EP04742386A EP1615925B1 (fr) 2003-03-31 2004-03-29 Derives d'imidazo-pyridine comme agonistes du recepteur de la melancortine
CNB2004800084919A CN100455581C (zh) 2003-03-31 2004-03-29 对黑皮质素受体具有亲和性的咪唑并吡啶衍生物
ES04742386T ES2327929T3 (es) 2003-03-31 2004-03-29 Derivados de imidazo-piridina como agonistas del receptor de melanocortina.
KR1020057018420A KR101102742B1 (ko) 2003-03-31 2004-03-29 멜라노코르틴 수용체에 대해 친화성을 갖는 이미다조피리딘 유도체
PCT/FR2004/000785 WO2004089951A1 (fr) 2003-03-31 2004-03-29 Derives d’imidazo-pyridine ayant une affinite sur des recepteurs de la melanocortine
RU2005133441/04A RU2358974C2 (ru) 2003-03-31 2004-03-29 Производные имидазо-пиридина, обладающие сродством к рецептору меланокортина
MXPA05010278A MXPA05010278A (es) 2003-03-31 2004-03-29 Derivados de imidazo-piridina como agonistas del receptor de la melanocortina.
AU2004228416A AU2004228416B9 (en) 2003-03-31 2004-03-29 Imidazopyridine derivatives as melanocortin receptor agonists or antagonists
NZ542763A NZ542763A (en) 2003-03-31 2004-03-29 Imidazopyridine derivatives as melanocortin receptor agonists
HK06111349.9A HK1090640B (en) 2003-03-31 2004-03-29 Imidazopyridine derivatives as melanocortin receptor agonists
CA2520855A CA2520855C (fr) 2003-03-31 2004-03-29 Derives d'imidazo-pyridine comme agonistes ou antagonistes du recepteur de la melanocortine
AT04742386T ATE432280T1 (de) 2003-03-31 2004-03-29 Imidazopyridinderivate als melanocortinrezeptoragonisten
DE602004021247T DE602004021247D1 (de) 2003-03-31 2004-03-29 Imidazopyridinderivate als melanocortinrezeptoragonisten
IL170834A IL170834A (en) 2003-03-31 2005-09-13 Imidazo-pyridine derivatives and their use as medicaments

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0303924A FR2852957B1 (fr) 2003-03-31 2003-03-31 Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament

Publications (2)

Publication Number Publication Date
FR2852957A1 FR2852957A1 (fr) 2004-10-01
FR2852957B1 true FR2852957B1 (fr) 2005-06-10

Family

ID=32947292

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0303924A Expired - Fee Related FR2852957B1 (fr) 2003-03-31 2003-03-31 Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament

Country Status (17)

Country Link
US (1) US7495009B2 (https=)
EP (1) EP1615925B1 (https=)
JP (1) JP4711948B2 (https=)
KR (1) KR101102742B1 (https=)
CN (1) CN100455581C (https=)
AT (1) ATE432280T1 (https=)
AU (1) AU2004228416B9 (https=)
BR (1) BRPI0408817A (https=)
CA (1) CA2520855C (https=)
DE (1) DE602004021247D1 (https=)
ES (1) ES2327929T3 (https=)
FR (1) FR2852957B1 (https=)
IL (1) IL170834A (https=)
MX (1) MXPA05010278A (https=)
NZ (1) NZ542763A (https=)
RU (1) RU2358974C2 (https=)
WO (1) WO2004089951A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2862971B1 (fr) * 2003-11-28 2006-03-24 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
TW200911803A (en) * 2007-07-16 2009-03-16 Organon Nv 6-phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives
EP2072050A1 (en) 2007-12-21 2009-06-24 Santhera Pharmaceuticals (Schweiz) AG Compounds with anti-emetic effect
EP2072516A1 (en) * 2007-12-21 2009-06-24 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine derivates as Melancortin-4 receptor antagonists
UY32138A (es) 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
EP2168965A1 (en) * 2008-09-25 2010-03-31 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine, imidazopyrazine, imidazopyridazine and imidazopyrimidine derivatives as melanocortin-4 receptor antagonists
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP5557845B2 (ja) 2008-10-31 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
UY32470A (es) 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
CN103168032A (zh) 2010-08-05 2013-06-19 安美基公司 抑制间变性淋巴瘤激酶的苯并咪唑和氮杂苯并咪唑化合物
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
US8759537B2 (en) 2010-08-20 2014-06-24 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
US8486968B2 (en) 2010-12-10 2013-07-16 Boehringer Ingelheim International Gmbh Compounds
US8466186B2 (en) 2010-12-10 2013-06-18 Boehringer Ingelheim International Gmbh Compounds
UY33779A (es) 2010-12-10 2012-07-31 Boehringer Ingelheim Int ?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas?
WO2012100342A1 (en) 2011-01-27 2012-08-02 Université de Montréal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
BR112013021236B1 (pt) 2011-02-25 2021-05-25 Merck Sharp & Dohme Corp composto derivado de benzimidazol, e, composição
CA2862444A1 (en) 2011-12-29 2013-07-04 Rhythm Metabolic, Inc. Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
JP2015515472A (ja) * 2012-04-06 2015-05-28 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害薬
US9527875B2 (en) 2012-08-02 2016-12-27 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
RU2015140066A (ru) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. Противодиабетические бициклические соединения
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
RU2020120797A (ru) 2013-03-15 2020-07-02 Ритм Фармасьютикалз, Инк. Пептидные композиции
PL2970389T3 (pl) 2013-03-15 2021-03-08 Rhythm Pharmaceuticals, Inc. Kompozycje farmaceutyczne
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US9067914B1 (en) 2013-12-10 2015-06-30 Genzyme Corporation Tropomyosin-related kinase (TRK) inhibitors
TWI696621B (zh) 2014-12-18 2020-06-21 美商健臻公司 原肌球蛋白相關激酶（ｔｒｋ）抑制劑之醫藥調配物
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
WO2019158731A1 (en) * 2018-02-16 2019-08-22 Ucb Biopharma Sprl Pharmaceutical 6,5 heterobicyclic ring derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4416433A1 (de) * 1994-05-10 1995-11-16 Hoechst Ag Cyclohexan-Derivate, Verfahren zu ihrer Herstellung und die Verwendung der Verbindungen zur Behandlung von Krankheiten
DE19503160A1 (de) * 1995-02-01 1996-08-08 Bayer Ag Verwendung von Phenylcyclohexylcarbonsäureamiden
UA62972C2 (en) * 1997-07-03 2004-01-15 Application of imidazopyrimidins and imidazopyridins for the treatment of neural disorders
WO2000074679A1 (en) * 1999-06-04 2000-12-14 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
MXPA02001160A (es) * 1999-08-04 2002-07-02 Millennium Pharm Inc Compuestos que se unen a los receptores para melanocortina-4, y metodo de uso de estos.
AU2001236919A1 (en) 2000-02-09 2001-08-20 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Premeiotic and postmeiotic origin of teratomas: isolated teratoma stem cells for therapeutic uses
EP1289526A4 (en) * 2000-05-30 2005-03-16 Merck & Co Inc MELANOCORTIN RECEPTOR AGONISTS
HUP0303494A3 (en) * 2000-12-15 2009-08-28 Vertex Pharma Parmaceutical compositions containing bacterial gyrase inhibitors and uses thereof
EP1465888A2 (en) * 2002-01-10 2004-10-13 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues

Also Published As

Publication number Publication date
KR20060002893A (ko) 2006-01-09
ES2327929T3 (es) 2009-11-05
DE602004021247D1 (de) 2009-07-09
KR101102742B1 (ko) 2012-01-05
IL170834A (en) 2010-12-30
AU2004228416B8 (en) 2010-03-04
NZ542763A (en) 2007-11-30
US20060173036A1 (en) 2006-08-03
ATE432280T1 (de) 2009-06-15
WO2004089951A1 (fr) 2004-10-21
CA2520855C (fr) 2014-05-13
WO2004089951A8 (fr) 2006-01-12
HK1090640A1 (zh) 2006-12-29
RU2358974C2 (ru) 2009-06-20
AU2004228416A1 (en) 2004-10-21
EP1615925A1 (fr) 2006-01-18
RU2005133441A (ru) 2006-05-10
CN100455581C (zh) 2009-01-28
AU2004228416B2 (en) 2010-02-11
US7495009B2 (en) 2009-02-24
CA2520855A1 (fr) 2004-10-21
JP2006522076A (ja) 2006-09-28
AU2004228416B9 (en) 2010-03-11
MXPA05010278A (es) 2005-11-17
EP1615925B1 (fr) 2009-05-27
FR2852957A1 (fr) 2004-10-01
JP4711948B2 (ja) 2011-06-29
BRPI0408817A (pt) 2006-04-04
CN1768058A (zh) 2006-05-03

Similar Documents

Publication Publication Date Title
FR2852957B1 (fr) Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament
MXPA05009015A (es) Nuevos derivados de bencimidazol e imidazo-piridina y su utilizacion como medicamentos.
MA26599A1 (fr) Nouveaux derives de benzenesulfonyle, leur preparation et leur application en tant que medicament
EE200300033A (et) Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
EP1988910A4 (en) ACRYLOYLOXYETHYLPHOSPHORYLCHOLIN-CONTAINING POLYMER CONJUGATES AND THEIR PREPARATION
CY1106032T1 (el) Υποκατασταθεισες πυραζολες
BR0108395A (pt) Derivados de pirrolopirimidinona, processos de preparação e uso
MA27366A1 (fr) Nouveaux derives de thiophenylglycoside, methodes pour leur production, medicaments contenant lesdits composes et leur utilisation
AR021844A1 (es) Derivados de propanolamina aril-sustituidos, procedimientos para su preparacion, medicamentos que contienen estos compuestos y su utilizacion
BRPI0415525A (pt) derivados de imidazola e seu uso como agentes farmacêuticos
DE69718734D1 (de) Bicyclische aromatische verbindungen
BRPI0411891A (pt) pirazol[3,4-b]piridin-6-onas como inibidores de gsk-3
CL2003002565A1 (es) Compuestos derivados de 3h-quinazolin-4-ona, su proceso de preparacion, composicion farmaceutica que los contiene, y uso en el tratamiento y prevencion de enfermedades mediadas por inhibidores de mao-b, tales como la enfermedad de alzheimer y demenci
FR2859997B1 (fr) Nouveaux derives d'indolizine 1,2,3,6,7,8 substituee, inhibiteurs des fgfs, leur procede de preparation et les compositions pharmaceutiques les contenant.
BR0112807A (pt) Derivados de indol e sua aplicação como medicamento
PT1768985E (pt) Derivados de pirimido-benzimidazole e sua utilização como agonistas ou antagonistas dos receptores das melanocortinas
FR2920774B1 (fr) Nouveaux derives de n-phenul acatamide, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contentant
TR200100637T2 (tr) Yeni doğal ürün türevleri
EP1509220A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SEBORRHOE WITH 4-HYDROXY-5-METHOXY-4-2-METHYL-3 (3-METHYL-2-BUTENYL) -2-OXIRANYL-1-OXASPIRO 2.5 OCTAN-6-ON
FR2763592B1 (fr) Nouveaux derives glycosyles des ginkgolides, leur application en tant que medicaments et compositions pharmaceutiques les contenant
FR2900404B1 (fr) Nouveaux derives d'imidazoles, leur preparation et leur utilisation en tant que medicament
SE0300457D0 (sv) Novel compounds
BR0309412A (pt) Indol-2-onas como inibidores seletivos da ciclooxigenase-2
BRPI0409793A (pt) 4-,6- ou 7-hidroxiindóis com grupos n-óxido e sua aplicação como produtos terapêuticos
FR2857026B1 (fr) Produit immunomodulateur obtenu a partir d'une culture de bifidobacterium et compositions le contenant

Legal Events

Date Code Title Description
CA Change of address
CD Change of name or company name
ST Notification of lapse

Effective date: 20151130